You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Guidelines & Advice
About Guidelines Email Guidelines Team

Systemic Treatment of Acute Myeloid Leukemia (AML)

ID: 12-9 Jan 2016
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
A.C. Schuh, G.G. Fletcher, B. Leber, M. Sabloff, Systemic Treatment Disease Site Group

Guideline Objective

The primary objective was to make recommendations regarding the most effective intensive systemic treatment of acute myeloid leukemia (AML) in adult patients. A secondary objective was to make recommendations regarding use of patient characteristics to determine appropriate treatment.

Patient Population

The target population is adult patients with AML (excluding acute promyelocytic leukemia) who are deemed suitable for intensive treatment.

Intended Guideline Users

The intended users are hematologists, oncologists, nurses, and pharmacists.

Research Question(s)

  1. What is the most effective systemic induction treatment for adults with previously untreated AML who can tolerate intensive treatment?
  2. What is the most effective systemic post-remission treatment (consolidation and/or maintenance, excluding stem cell transplant) for adults with previously untreated AML?
  3. What is the most effective systemic treatment (reinduction, consolidation, maintenance; not including stem cell transplant) for adults with relapsed or refractory AML who can tolerate intensive treatment?
  4. Which patient characteristics are most important when making treatment decisions?
pdf download Summary (PDF) (192.97 KB)
pdf download Full Report (PDF) (4.52 MB)